All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Q3 2025: 10 FDA Decisions to Watch in the Realm of Oncology

June 24th 2025

Here is your Q3 2025 preview spotlighting 10 FDA decisions to watch, including upcoming PDUFAs for sunvozertinib, linvoseltamab, vuslimogene oderparepvec, and more.

Wheat Germ May Boost Immunotherapy in Cancer Patients

June 24th 2025

A clinical trial is testing an extract that could unlock the body’s natural ability to fight cancer.

Serplulimab Earns UK Approval for First-Line ES-SCLC

June 24th 2025

Serplulimab is now the only anti–PD-1 monoclonal antibody approved by the MHRA for patients with extensive-stage small cell lung cancer in the first line.

THE001 Plus Regional Hyperthermia Shows Early Efficacy, Safety in Pretreated Soft Tissue Sarcoma

June 24th 2025

THE001 plus regional hyperthermia was safe and led to responses in patients with heavily pretreated soft tissue sarcoma.

Skipping Surgery in Early HER2+ Breast Cancer or TNBC? Phase 2 Trial Data Highlight Feasibility of Selective Omission

June 24th 2025

Henry Kuerer, MD, PhD, discusses considerations for the selective omission of surgery in HER2-positive breast cancer or triple-negative breast cancer.

Final PICCOLO Data Underscore Mirvetuximab Soravtansine’s Efficacy in Later-Line Frα+ Platinum-Sensitive Ovarian Cancer

June 24th 2025

Mirvetuximab soravtansine continues to show efficacy and safety in final analysis of the phase 2 PICCOLO study.

MRD Negativity Is Prognostic for Survival and Maintained With Frontline Acalabrutinib/BR in MCL

June 24th 2025

Acalabrutinib plus BR prolonged duration of MRD negativity vs BR alone in previously untreated MCL, supporting the use of MRD as a prognostic biomarker.

Gecacitinib Elicits Hematologic Responses, Spleen and Symptom Reduction Across Anemic Subgroups in Myelofibrosis

June 23rd 2025

Gecacitinib, a dual JAK/ACVR1 inhibitor, showed spleen volume, symptom and anemia improvements in patients with myelofibrosis.

Real-World Data Help to Inform Treatment Selection in Metastatic Urothelial Carcinoma

June 23rd 2025

Amit Mehta, MD, discusses the landscape of metastatic urothelial carcinoma, including data updates as well as treatment selection and safety considerations.

FDA Grants Accelerated Approval to Dato-DXd for EGFR+ NSCLC

June 23rd 2025

The FDA approved Dato-DXd for previously treated, locally advanced or metastatic, EGFR-mutated non–small cell lung cancer.

Newsweek Names Roswell Park to America's Best Cancer Hospitals List

June 23rd 2025

Roswell Park Comprehensive Cancer Center has been added to Newsweek’s list of America’s Best Cancer Hospitals for 2025.

CHMP Recommends Isatuximab Plus VRd for Transplant-Eligible, Newly Diagnosed Myeloma

June 23rd 2025

CHMP issues positive opinion for isatuximab plus VRd in transplant-eligible, newly diagnosed multiple myeloma.

Zanzalintinib Plus Atezolizumab Boosts OS in Previously Treated, Non–MSI-H mCRC

June 23rd 2025

Zanzalintinib plus atezolizumab improved overall survival in previously treated, non–MSI-H metastatic colorectal cancer.

First-Line Ibrutinib Plus Venetoclax Demonstrates Activity in Older Patients With MCL

June 23rd 2025

Ibrutinib plus venetoclax led to complete responses and durable remissions in the first-line treatment of older patients with MCL.

Oncology Fellowship Often Fails to Include Training in Gender Equity Issues

June 23rd 2025

Ana Velázquez Mañana, MD, MSc, discusses survey findings that revealed gender equity training for oncology fellows is often lacking.

Cilta-Cel Continues to Sustain PFS and OS in Relapsed/Refractory Multiple Myeloma

June 23rd 2025

Surbhi Sidana, MD, highlighted the continued efficacy of cilta-cel in patients with relapsed/refractory multiple myeloma, according to an ITT analysis.

First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer

June 22nd 2025

Rucaparib maintenance improved PFS in HRD-negative advanced ovarian cancer, irrespective of baseline prognostic factors.

Five Under 5: Top Oncology Videos for the Week of 6/15

June 22nd 2025

The top 5 OncLive videos of the week cover insights in CLL, multiple myeloma, follicular lymphoma, and extrapulmonary neuroendocrine carcinomas.

Raludotatug Deruxtecan Shows Activity in Platinum-Sensitive Ovarian Cancer

June 21st 2025

Raludotatug deruxtecan showed promising clinical activity in patients with heavily pretreated, platinum-sensitive ovarian cancer.

The OncFive: Top Oncology Articles for the Week of 6/15

June 21st 2025

Tafasitamab combination gets approval in follicular lymphoma, FDA declines to expand label for talazoparib plus enzalutamide in mCRPC, and more.